Biosense Webster enrolls and treats first patient in QDOT AF study

Belgium Hospital Hosts Successful World-first Procedure

Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its QDOT AF Study. The study will evaluate the delivery of high power, short duration ablation with QDOT MICRO, a novel radiofrequency (RF) ablation catheter for the treatment of paroxysmal atrial fibrillation (AF). The first AF patient was treated at OLV Hospital in Aalst, Belgium, one of eight centers in Europe part of the study that will be enrolling up to 50 patients.

AF is fast becoming one of the world’s most significant health issues – affecting 14 million people across Europe, the Middle East and Africa, as well as placing a critical burden on healthcare systems with up to 2.5% of total healthcare expenditure associated with the disease.

QDOT MICRO is a next generation catheter designed to treat AF in a catheter ablation procedure. In what will be a world-first, it delivers 90 watts of RF power in a four-second temperature-controlled catheter ablation session. Its optimized temperature control and micro-electrode technology is designed to provide more efficient and consistent lesion creation with advanced diagnostics, while simplifying the technique and reducing total ablation time.

“The concept of high power short duration ablation is novel and a potentially groundbreaking advancement for the industry,” said Tom De Potter, MD, FEHRA, Associate Director, Cardiovascular Center Department of Cardiology, Electrophysiology Section at OLV Hospital. “The new modality could result in improvements in clinical outcomes and procedural efficiencies and I look forward to further investigation.” Dr De Potter performed the first QDOT MICRO procedure, and is one of the study clinical investigators.

QDOT MICRO, which is only available for investigational use in Europe, is a steerable multi-electrode catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit RF current to the catheter tip electrode for ablation purposes. In addition to force-sensing technology, the catheter incorporates six thermocouple temperature sensors and three micro electrodes embedded in its tip.

“For over 20 years Biosense Webster has pioneered the development of atrial fibrillation treatment” explains Gabriele Fischetto (Vice President of Johnson & Johnson Cardiovascular Specialty Solutions in EMEA). “QDOT MICRO continues our commitment to deliver solutions that help clinicians heal more hearts and has the potential to increase the standard of treatment for paroxysmal atrial fibrillation”.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Johnson & Johnson. (2019, June 19). Biosense Webster enrolls and treats first patient in QDOT AF study. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20180511/Biosense-Webster-enrolls-and-treats-first-patient-in-QDOT-AF-study.aspx.

  • MLA

    Johnson & Johnson. "Biosense Webster enrolls and treats first patient in QDOT AF study". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20180511/Biosense-Webster-enrolls-and-treats-first-patient-in-QDOT-AF-study.aspx>.

  • Chicago

    Johnson & Johnson. "Biosense Webster enrolls and treats first patient in QDOT AF study". News-Medical. https://www.news-medical.net/news/20180511/Biosense-Webster-enrolls-and-treats-first-patient-in-QDOT-AF-study.aspx. (accessed November 21, 2024).

  • Harvard

    Johnson & Johnson. 2019. Biosense Webster enrolls and treats first patient in QDOT AF study. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20180511/Biosense-Webster-enrolls-and-treats-first-patient-in-QDOT-AF-study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Biosense Webster enrolls and treats first AF patient in clinical study of new RF balloon catheter